Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Elderly Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

NCT03298672
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NDX-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

NCT03928353
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
View directory record Official record
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects

NCT01365624
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketorolac tromethamine
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

NCT01673451
View directory record Official record
Conditions
CNS
Interventions
E2006, Placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Culver City, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PA-001 Ph.1 Study in Healthy and Elderly Subjects

NCT07518771
View directory record Official record
Conditions
COVID - 19
Interventions
PA-001
Drug
Lead sponsor
PeptiDream Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 2, 2026, 1:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

NCT00945581
View directory record Official record
Conditions
Aged
Interventions
Experimental Nutritional Powder Formula, Placebo comparator
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
60 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

NCT01766921
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
1,393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Hollywood, Florida • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

NCT02587520
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years and older
Enrollment
1,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 2, 2026, 1:00 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829
View directory record Official record
Conditions
Excessive Daytime Sleepiness
Interventions
ORX142 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Lincoln, Nebraska • Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

NCT03500679
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wichita, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

NCT01013610
View directory record Official record
Conditions
Mild Alzheimer's Disease
Interventions
LNK-754, Placebo
Drug
Lead sponsor
Link Medicine Corporation
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

NCT05745207
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine 134612, Menactra®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
View directory record Official record
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

NCT01079819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

NCT01209104
View directory record Official record
Conditions
Nutritional Status
Interventions
GSK1325756
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCT06225115
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
KYN-5356, placebo
Drug
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 2, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

NCT00845429
View directory record Official record
Conditions
Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions
Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
15
States / cities
Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 2, 2026, 1:00 AM EDT